• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肌萎缩侧索硬化症中易聚集的致病性超氧化物歧化酶1变体:来自计算基因组学和进化保守性的见解

Aggregation-Prone Pathogenic SOD1 Variants in Amyotrophic Lateral Sclerosis: Insights from Computational Genomics and Evolutionary Conservation.

作者信息

Anjum Farah, Bakhuraysah Maha M, Hulbah Maram Jameel, Alsharif Abdulaziz, Mohammad Taj, Hassan Md Imtaiyaz

机构信息

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.

King Salman Center for Disability Research, Riyadh, 11614, Saudi Arabia.

出版信息

J Mol Neurosci. 2025 Aug 7;75(3):99. doi: 10.1007/s12031-025-02388-7.

DOI:10.1007/s12031-025-02388-7
PMID:40772974
Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration and a median survival of 3-5 years post-diagnosis. While the etiology of ALS remains elusive, mutations in SOD1, encoding the Cu/Zn superoxide dismutase enzyme, are strongly associated with familial ALS (fALS). These mutations promote a toxic gain-of-function, primarily through SOD1 misfolding and aggregation. We systematically assessed 244 SOD1 missense mutations using a multi-tiered computational framework encompassing structural, functional, and pathogenic predictors. Sequence-based predictors (SIFT, PolyPhen-2, FATHMM) and structure-guided tools (mCSM, PremPS, DynaMut2) identified 79 destabilizing mutations, 64 of which were classified as pathogenic by phenotype predictors (PhD-SNP, SNPs&GO, MutPred2). Twelve mutations resided in evolutionarily conserved regions, with eight (D84N, G73C, H72Y, P67A, P67R, P67S, R144G, S60I) exhibiting pronounced aggregation propensity via SODA analysis. Notably, H72Y disrupts a zinc-binding residue critical for structural integrity and catalysis. Protein-protein interaction networks linked SOD1 to ALS-associated pathways, highlighting its involvement in oxidative stress and protein homeostasis. Our integrative approach highlights the power of computational genomics in unraveling mutation-driven SOD1 dysfunction, offering mechanistic insights into ALS pathogenesis and guiding therapeutic strategies focused on aggregation-prone variants.

摘要

肌萎缩侧索硬化症(ALS)是一种致命的神经退行性疾病,其特征为运动神经元进行性退化,诊断后的中位生存期为3至5年。虽然ALS的病因仍不明确,但编码铜/锌超氧化物歧化酶的SOD1基因突变与家族性ALS(fALS)密切相关。这些突变主要通过SOD1错误折叠和聚集促进毒性功能获得。我们使用包含结构、功能和致病性预测因子的多层计算框架,系统评估了244个SOD1错义突变。基于序列的预测因子(SIFT、PolyPhen-2、FATHMM)和结构导向工具(mCSM、PremPS、DynaMut2)识别出79个不稳定突变,其中64个被表型预测因子(PhD-SNP、SNPs&GO、MutPred2)归类为致病性突变。12个突变位于进化保守区域,通过SODA分析,其中8个(D84N、G73C、H72Y、P67A、P67R、P67S、R144G、S60I)表现出明显的聚集倾向。值得注意的是,H72Y破坏了对结构完整性和催化至关重要的锌结合残基。蛋白质-蛋白质相互作用网络将SOD1与ALS相关途径联系起来,突出了其在氧化应激和蛋白质稳态中的作用。我们的综合方法突出了计算基因组学在揭示突变驱动的SOD1功能障碍方面的作用,为ALS发病机制提供了机制性见解,并指导针对易聚集变体的治疗策略。

相似文献

1
Aggregation-Prone Pathogenic SOD1 Variants in Amyotrophic Lateral Sclerosis: Insights from Computational Genomics and Evolutionary Conservation.肌萎缩侧索硬化症中易聚集的致病性超氧化物歧化酶1变体:来自计算基因组学和进化保守性的见解
J Mol Neurosci. 2025 Aug 7;75(3):99. doi: 10.1007/s12031-025-02388-7.
2
Seeding activity of human superoxide dismutase 1 aggregates in familial and sporadic amyotrophic lateral sclerosis postmortem neural tissues by real-time quaking-induced conversion.通过实时液滴式震动转换技术研究家族性和散发性肌萎缩性侧索硬化症患者死后神经组织中人类超氧化物歧化酶 1 聚集物的成核活性。
Acta Neuropathol. 2024 Jun 17;147(1):100. doi: 10.1007/s00401-024-02752-8.
3
Investigating the Stability, Flexibility, and Phase Separation Properties of H46R and H80R Disease Mutants of SOD1: Insights into ALS Pathogenesis.研究超氧化物歧化酶1(SOD1)的H46R和H80R疾病突变体的稳定性、灵活性和相分离特性:对肌萎缩侧索硬化症发病机制的见解
Biochemistry. 2025 Aug 5;64(15):3358-3371. doi: 10.1021/acs.biochem.5c00289. Epub 2025 Jul 17.
4
Phenotypic Characterization of ALS-Causing SOD1 Mutations Affecting Polypeptide Length.影响多肽长度的肌萎缩侧索硬化症致病超氧化物歧化酶1突变的表型特征
Hum Mutat. 2025 Jun 16;2025:9792233. doi: 10.1155/humu/9792233. eCollection 2025.
5
Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1.色氨酸残基在 TDP-43 和 SOD1 中调节 SOD1 的交叉播种和毒性。
J Biol Chem. 2024 May;300(5):107207. doi: 10.1016/j.jbc.2024.107207. Epub 2024 Mar 22.
6
Behavioral and Cognitive Phenotypes of Patients With Amyotrophic Lateral Sclerosis Carrying SOD1 Variants.携带 SOD1 变异的肌萎缩侧索硬化症患者的行为和认知表型。
Neurology. 2022 Oct 31;99(18):e2052-e2062. doi: 10.1212/WNL.0000000000201044.
7
Restoring Homeostasis: Treating Amyotrophic Lateral Sclerosis by Resolving Dynamic Regulatory Instability.恢复体内平衡:通过解决动态调节不稳定来治疗肌萎缩侧索硬化症
Int J Mol Sci. 2025 Jan 21;26(3):872. doi: 10.3390/ijms26030872.
8
Network analysis of the cerebrospinal fluid proteome reveals shared and unique differences between sporadic and familial forms of amyotrophic lateral sclerosis.脑脊液蛋白质组的网络分析揭示了散发性和家族性肌萎缩侧索硬化症形式之间的共同和独特差异。
Mol Neurodegener. 2025 May 15;20(1):58. doi: 10.1186/s13024-025-00838-9.
9
Prevalence of SOD1 and C9orf72 Variants Among French ALS Population: The GENIALS Study.法国肌萎缩侧索硬化症患者中SOD1和C9orf72基因变异的患病率:GENIALS研究
Eur J Neurol. 2025 Aug;32(8):e70302. doi: 10.1111/ene.70302.
10
Desloratadine alleviates ALS-like pathology in hSOD1 mice via targeting 5HTR on activated spinal astrocytes.地氯雷他定通过靶向激活的脊髓星形胶质细胞上的 5HTR 减轻 hSOD1 小鼠的 ALS 样病变。
Acta Pharmacol Sin. 2024 May;45(5):926-944. doi: 10.1038/s41401-023-01223-2. Epub 2024 Jan 29.

本文引用的文献

1
Inhibitory effect of Fisetin against the aggregation process of SOD1 E100K mutant: computer-based drug design as a potential therapeutic for ALS disease.非瑟酮对超氧化物歧化酶1 E100K突变体聚集过程的抑制作用:基于计算机的药物设计作为肌萎缩侧索硬化症的潜在治疗方法。
Front Chem. 2025 May 22;13:1569777. doi: 10.3389/fchem.2025.1569777. eCollection 2025.
2
Mutation/metal deficiency in the "electrostatic loop" enhanced aggregation process in apo/holo SOD1 variants: implications for ALS diseases.“静电环”中的突变/金属缺乏增强了载脂蛋白/全酶SOD1变体的聚集过程:对肌萎缩侧索硬化症的影响。
BMC Chem. 2024 Sep 19;18(1):177. doi: 10.1186/s13065-024-01289-x.
3
Amyotrophic Lateral Sclerosis (ALS): An Overview of Genetic and Metabolic Signaling Mechanisms.
肌萎缩侧索硬化症(ALS):遗传和代谢信号传导机制概述
CNS Neurol Disord Drug Targets. 2025;24(2):83-90. doi: 10.2174/0118715273315891240801065231.
4
Most mutations are pathogenic, and their identification can lead to early access to treatment.大多数突变是致病性的,对它们的识别能够使患者早日获得治疗。
J Neurol Neurosurg Psychiatry. 2024 Nov 18;95(12):1219-1220. doi: 10.1136/jnnp-2024-333939.
5
Fighting against amyotrophic lateral sclerosis (ALS) with flavonoids: a computational approach to inhibit superoxide dismutase (SOD1) mutant aggregation.用类黄酮对抗肌萎缩侧索硬化症(ALS):一种抑制超氧化物歧化酶(SOD1)突变体聚集的计算方法。
J Biomol Struct Dyn. 2025 Jan;43(1):419-436. doi: 10.1080/07391102.2023.2281641. Epub 2023 Nov 17.
6
Polyphenolic flavonoid compounds act as the inhibitory potential of aggregation process: Implications for the prevention and therapeutics against FALS-associated D101G SOD1 mutant.多酚类黄酮化合物作为聚集过程的抑制潜力:对预防和治疗 FALS 相关 D101G SOD1 突变体的影响。
Comput Biol Chem. 2023 Dec;107:107967. doi: 10.1016/j.compbiolchem.2023.107967. Epub 2023 Oct 6.
7
Protein kinetics of superoxide dismutase-1 in familial and sporadic amyotrophic lateral sclerosis.家族性和散发性肌萎缩侧索硬化症中超氧化物歧化酶 1 的蛋白动力学。
Ann Clin Transl Neurol. 2023 Jun;10(6):1012-1024. doi: 10.1002/acn3.51784. Epub 2023 Apr 29.
8
Using evolutionary data to make sense of macromolecules with a "face-lifted" ConSurf.利用进化数据,通过“改头换面”的 ConSurf 来理解大分子。
Protein Sci. 2023 Mar;32(3):e4582. doi: 10.1002/pro.4582.
9
The Role of Superoxide Dismutase 1 in Amyotrophic Lateral Sclerosis: Identification of Signaling Pathways, Regulators, Molecular Interaction Networks, and Biological Functions through Bioinformatics.超氧化物歧化酶1在肌萎缩侧索硬化症中的作用:通过生物信息学鉴定信号通路、调节因子、分子相互作用网络及生物学功能
Brain Sci. 2023 Jan 15;13(1):151. doi: 10.3390/brainsci13010151.
10
Molecular Investigations of Protein Aggregation in the Pathogenesis of Amyotrophic Lateral Sclerosis.分子研究在肌萎缩侧索硬化症发病机制中的蛋白聚集。
Int J Mol Sci. 2022 Dec 31;24(1):704. doi: 10.3390/ijms24010704.